Abstract:Schiff base derivative of 2‐aminothiazole and 2,4‐dihydroxybenzaldehyde in addition to its Co (II), Cu (II), Zn (II) and Th (IV) chelates were prepared. Structure characterization of the prepared compounds by applying all available analytical and spectroscopic tools. The acquired data showed the chelation of the ligand with metal through the nitrogen of the azo group and deprotonated ortho phenolic oxygen. Investigation of antimicrobial and anticancer activity for the ligand and in addition to docking studied through interaction with 3S7S and 2JW2. For further pharmaceutical applications, a novel Schiff base derivative of aminothiazole and its Co (II), Cu (II), Zn (II), and Th (IV) chelates were designed and prepared. For this purpose, 2‐aminothiazole and 2,4‐dihydroxybenzaldehyde have been coupled before the complexation reaction with the metal salts. Elemental analysis, FT‐IR, 1HNMR, UV–Vis spectra, transmission electron microscopy (TEM), X‐ray powder diffraction (XRD), molar conductance, and magnetic moment measurements were used to determine the structural formula of the ligand and its produced chelates. The acquired data pointed out that the ligand was chelated with metal through the nitrogen of azo group and deprotonated ortho phenolic oxygen atoms. In Cu (II) complex the copper ion chelated with two ligand molecules, whereas in other complexes the metal binds with one molecule only of ligand. It was shown by XRD patterns and high‐resolution TEM images that the complex particles had a uniform distribution across the chelates' surfaces and were nanometric in size. Extremely, antimicrobial and anticancer activity for the prepared ligand and complexes were investigated, which showed high activity, especially after complex formation. Docking studies have been performed to predict the compounds' efficacy as antitumor agents through their interaction with the co‐crystal structure of proteins for breast cancer cells (PDB ID: 3S7S) and protein of liver cancer 2 (PDB ID: 2JW2). The experimental results of the anticancer activity showed promising results, especially for Cu (II) compound which exhibited the greatest antitumor efficacy (IC50 = 12.81 μg/ml) contra HepG‐2 carcinoma and Mcf‐7 cells (IC50 = 18.92 ± 0.91 μg/ml). Antimicrobial activity against the strains Klebsiella pneumoniae (K. pneumoniae), Escherichia coli (E. coli), Staphylococcus aureus (S. aureus), Bacillus subtilis (B. subtilis), C. albicans (C. albicans), and Aspergillus niger (A. niger) also gave very promising results when it is compared with the standard drugs.

Deliberate-Characterization for Ni(II)-Schiff Base Complexes: Promising In-Vitro Anticancer Feature that Matched MOE Docking-Approach

Designing metal chelates of halogenated sulfonamide Schiff bases as potent nonplatinum anticancer drugs using spectroscopic, molecular docking and biological studies

Synthesis and Structural Elucidation for New Schiff Base Complexes; Conductance, Conformational, MOE-Docking and Biological Studies

Structural versatility in nickel (II) complexes of a hydrazone ligand based on alloxan: Preparation, spectroscopic, DFT, anticancer, and molecular docking studies

Synthesis, Molecular Docking and Antitumor Activity of New Dithiazoles

New dinuclear Schiff base nickel complex: Investigation of intermolecular interactions via theoretical calculations, molecular docking studies and ADMET profiling approaches survey

Synthesis and Characterization for New Nanometer Cu(II) Complexes, Conformational Study and Molecular Docking Approach Compatible with Promising in Vitro Screening

New Metal Complexes Incorporating Schiff Base Ligand Based on Pyridine Moiety: Synthesis, Spectral Characterization, DFT, Biological Evaluation, and Molecular Docking

Synthesis, Characterization, Investigation of Anticancer Activity and Molecular Docking Studies of N2O2 Type Schiff Base Ligand and Metal Complexes

Structural Design, Anticancer Evaluation, and Molecular Docking of Newly Synthesized Ni(II) Complexes with ONS-Donor Dithiocarbazate Ligands

A comprehensive study on synthesis and crystal structures of Cu(II) and Ni(II) complexes: In vitro and in silico evaluation of biomolecular interactions, antiproliferative activities and molecular docking

Synthesis, crystal structures and anticancer studies of Ni (II), Co (III) and Zn (II) complexes based on 5-bromosalicylaldehyde- 2-(2-aminophenyl)benzimidazole Schiff base

Synthesis, characterization, antimicrobial, molecular docking simulation, and antitumor assays of nanometric complexes based on new thiazole Schiff base derivative

Development of Novel Nano-Sized Imine Complexes Using Coriandrum sativum Extract: Structural Elucidation, Non-Isothermal Kinetic Study, Theoretical Investigation and Pharmaceutical Applications

Synthesis, Characterization and Breast Anti-cancer Activity of Iron(II), Cobalt(II), Nickel(II) and Copper(II) Complexes with a Hexadentate Schiff Base Ligand Derived from 2,5-Dihydroxy-1,4-benzoquinone with 5-Amino-2-methylphenol

Synthesis, Crystal Structure, Biomolecular Interactions and Anticancer Properties of Ni(II), Cu(II) and Zn(II) Complexes Bearing S-allyldithiocarbazate

Synthesis of Amino Acid Schiff Base Nickel (II) Complexes as Potential Anticancer Drugs In Vitro

Theoretical studies and evaluation of anticancer properties of two cobalt(III) Schiff base complexes derived from 3,5-dichloro-2-hydroxybenzaldehyde and 1,2-phenylene diamine

Synthesis, Characterization, Molecular Docking, Cytotoxicity, and Antimicrobial Activity of Schiff Base Ligand and Its Metal Complexes

Dithiocarbazate ligands and their Ni(II) complexes with potential biological activity: Structural, antitumor and molecular docking study

Novel Mn(II) and Cu(II) metal complexes with sulfa drug-derived ligands as potent antimicrobial and anticancer agents: In vitro studies, ADMET profile and molecular docking